- Home
- BWIN vs XENE Comparison
BWIN vs XENE Comparison
Compare BWIN & XENE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- BWIN
- XENE
- Stock Information
- Founded
- BWIN 2011
- XENE 1996
- Country
- BWIN United States
- XENE Canada
- Employees
- BWIN N/A
- XENE N/A
- Industry
- BWIN Specialty Insurers
- XENE Biotechnology: Pharmaceutical Preparations
- Sector
- BWIN Finance
- XENE Health Care
- Exchange
- BWIN Nasdaq
- XENE Nasdaq
- Market Cap
- BWIN 3.1B
- XENE 3.3B
- IPO Year
- BWIN 2019
- XENE 2014
- Fundamental
- Price
- BWIN $41.23
- XENE $38.52
- Analyst Decision
- BWIN Buy
- XENE Strong Buy
- Analyst Count
- BWIN 6
- XENE 7
- Target Price
- BWIN $44.80
- XENE $56.00
- AVG Volume (30 Days)
- BWIN 536.9K
- XENE 424.9K
- Earning Date
- BWIN 02-25-2025
- XENE 02-27-2025
- Dividend Yield
- BWIN N/A
- XENE N/A
- EPS Growth
- BWIN N/A
- XENE N/A
- EPS
- BWIN N/A
- XENE N/A
- Revenue
- BWIN $1,343,793,000.00
- XENE N/A
- Revenue This Year
- BWIN $15.96
- XENE N/A
- Revenue Next Year
- BWIN $13.09
- XENE $1,600.08
- P/E Ratio
- BWIN N/A
- XENE N/A
- Revenue Growth
- BWIN 13.89
- XENE N/A
- 52 Week Low
- BWIN $21.70
- XENE $35.53
- 52 Week High
- BWIN $55.82
- XENE $50.99
- Technical
- Relative Strength Index (RSI)
- BWIN 55.23
- XENE 42.98
- Support Level
- BWIN $34.78
- XENE $36.90
- Resistance Level
- BWIN $38.70
- XENE $41.03
- Average True Range (ATR)
- BWIN 1.35
- XENE 1.41
- MACD
- BWIN 0.69
- XENE 0.03
- Stochastic Oscillator
- BWIN 92.81
- XENE 30.39
About BWIN The Baldwin Insurance Group Inc. Class A Common Stock
The Baldwin Insurance Group Inc is a United States-based insurance distribution firm. Its products include Business Insurance, Benefits Consulting, Reinsurance, Specialty MGA, Embedded Insurance., Personal insurance, etc.
About XENE Xenon Pharmaceuticals Inc.
Xenon Pharmaceuticals Inc is a clinical-stage biopharmaceutical company committed to developing therapeutics to improve the lives of patients with neurological disorders, including rare central nervous system, or CNS, conditions. The product candidates of the group include XEN1101, XEN901, and XEN496 for Epilepsy, and Nav1.7 oral inhibitors for Pain. Geographically the activities are carried out throughout Canada.